Janney Montgomery Scott LLC 减持了 Viking Therapeutics 的股份，尽管该生物制药公司的股票在第一季度飙升了 1,242.9%。 Janney Montgomery Scott LLC cut its Viking Therapeutics holdings despite the biopharm's stock soaring 1,242.9% in Q1.

Janney Montgomery Scott LLC将维京治疗公司的股份减少了7.2%,出售了3 083个股份,持有39 529个股份,价值955 000美元。 Janney Montgomery Scott LLC reduced its holdings in Viking Therapeutics by 7.2%, selling 3,083 shares and holding 39,529 shares worth $955,000. Viking Therapeutics 是一家开发代谢和内分泌紊乱疗法的生物制药公司，其股价在第一季度上涨了 1,242.9%。 Viking Therapeutics, a biopharmaceutical firm developing therapies for metabolic and endocrine disorders, saw its stock rise 1,242.9% in the first quarter. 其主要药物VK2809正在肝病第二B阶段试验中。 Its lead drug, VK2809, is in Phase IIb trials for liver diseases. 尽管分析师的评分是正面的,但公司错过了收入估计数。 Despite positive analyst ratings, the company missed earnings estimates.